Colon and Rectal Cancers - Medications

(Page 2)

Highlights	Prevention	Radiation Treatment
Introduction	Diagnosis	Follow-up Testing
Causes	Staging	Treatment for Metastasized Colorectal Cancer
Symptoms	Prognosis	Resources
Risk Factors	Surgery	References
Dietary Factors	Medications

Advanced diagnostic techniques are under investigation for helping to select appropriate Stage II candidates for adjuvant therapy. None of these methods, however, are ready to be used routinely to help make treatment decisions. The decision whether to pursue chemotherapy for Stage II disease should be made after careful discussion between the patient and their oncologist, especially after features, such as bowel perforation or obstruction, are taken into account.

Chemotherapy for Stage III Patients with Colon Cancer. Since the early 1990s, adjuvant chemotherapy with 5-FU and leucovorin has been the standard of care for Stage III colon cancer. Numerous trials have shown that adjuvant chemotherapy in this setting reduces the absolute risk of death from colon cancer by approximately one-third and improves survival by 10%. Current clinical trials are investigating whether the addition of new chemotherapy drugs, such as irinotecan, oxaliplatin, capecitabine, and antibody therapies, will improve cure rates over 5-FU and leucovorin alone. However, most of these new drugs should currently not be used for adjuvant treatment of colon cancer unless as part of a clinical trial.

text continues below

Chemotherapy for Advanced Colorectal Cancer. Chemotherapy and radiation are generally used to reduce symptoms and prolong life in advanced colorectal cancer. Some experts suggest that chemotherapy should be considered for patients who are:

Able to carry out all normal activity without restriction.
Restricted in physically strenuous activity, but able to walk about and carry out light work.
Able to walk about and capable of all self care, but unable to carry out any work. Out of bed or chair for more than 50% of waking hours.

Chemotherapy in most studies offers a modest improvement in survival and often relieves symptoms. One 2003 study suggested that for these patients chemotherapy given intermittently has fewer toxic or serious adverse effects and may be as beneficial as continuous administration.

The following patients are unlikely to benefit from chemotherapy: